Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs

Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs
New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer's Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the 5HT6 receptor. This effect leads to the release of acetylcholine, an essential neurotransmitter that plays a key role in cognition, and whose levels are decreased in dementia. Intepirdine is orally administered and provided in combination with Aricept (donepezil), a drug approved by the U.S. Food and Drug A
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *